iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Maviret in HCV Treatment-Experienced
 
 
  FDA approves Mavyret (G/P - Abbvie) for Hepatitis C - (08/05/17)
 
FDA - G/P - Trials, Package Insert, MAVYRET approved to treat HCV - (08/05/17)
 
EASL: MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE - (04/24/17)
 
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14)
 
ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14)
 
A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance...... http://www.natap.org/2014/AASLD/AASLD_51.htm
 
EASL: Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects - (05/04/15)
 
EASL: Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15)
 

treatment

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org